In the case of SPTBN1, data support that its expression levels are significantly down-regulated in various human cancers such as digestive tract cancer, pancreatic cancer, hepatocellular carcinoma, and lung cancer, reducing SPTBN1 expression has been linked to cancer progression [53,56]. Here, SPTBN1 is linked to pancreatic neoplasm.